Mechanistic Studies of Semicarbazone Triapine Targeting Human Ribonucleotide Reductase in Vitro and in Mammalian Cells: TYROSYL RADICAL QUENCHING NOT INVOLVING REACTIVE OXYGEN SPECIES*

Triapine® (3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP)) is a drug in Phase II trials. One of its established cellular targets is the β₂ subunit of ribonucleotide reductase that requires a diferric-tyrosyl-radical [(Fe^III₂-Y·)(Fe^III₂)] cofactor for de novo DNA biosynthesis. Several mechanisms for 3-AP inhibition of β₂ have been proposed; one involves direct iron chelation from β₂, whereas a second involves Y· destruction by reactive oxygen species formed in situ in the presence of O₂ and reductant by Fe(II)-(3-AP). Inactivation of β₂ can thus arise from cofactor destruction by loss of iron or Y·. In vitro kinetic data on the rates of ⁵⁵Fe and Y· loss from [(⁵⁵Fe^III₂-Y·)(⁵⁵Fe^III₂)]-β₂ under aerobic and anaerobic conditions reveal that Y· loss alone is sufficient for rapid β₂ inactivation. Oxyblot^TM and mass spectrometric analyses of trypsin-digested inhibited β₂, and lack of Y· loss from H₂O₂ and O₂^˙̄ treatment together preclude reactive oxygen species involvement in Y· loss. Three mammalian cell lines treated with 5 μm 3-AP reveal Y· loss and β₂ inactivation within 30-min of 3-AP-exposure, analyzed by whole-cell EPR and lysate assays, respectively. Selective degradation of apo- over [(Fe^III₂-Y·)(Fe^III₂)]-β₂ in lysates, similar iron-content in β₂ immunoprecipitated from 3-AP-treated and untreated [⁵⁵Fe]-prelabeled cells, and prolonged (12 h) stability of the inhibited β₂ are most consistent with Y· loss being the predominant mode of inhibition, with β₂ remaining iron-loaded and stable. A model consistent with in vitro and cell-based biochemical studies is presented in which Fe(II)-(3-AP), which can be cycled with reductant, directly reduces Y· of the [(Fe^III₂-Y·)(Fe^III₂)] cofactor of β₂.